The use of neural progenitor cells (NPCs) is limited by the incomplete knowledge of the extracellular signals regulating their proliferation and survival. We report that cultured mouse NPCs express functional mGlu3 and mGlu5 metabotropic glutamate receptors. Pharmacological blockade of both receptors reduced NPC proliferation and survival, whereas activation of mGlu5 receptors substantially enhanced cell proliferation. Adult mice lacking mGlu5 receptors or treated with mGlu5 or mGlu3 receptor antagonists showed a dramatic reduction in the number of dividing neuroprogenitors present in the subventricular zone and in the dentate gyrus of the hippocampus. These data disclose a novel function of mGlu receptors and offer new potential strategies for the optimization of cell replacement therapy in neurodegenerative disorders.
Introduction
Neuroprogenitor cells (NPCs, variously referred to as neural progenitor cells or multipotent neural precursors) comprise a relatively undifferentiated population of cells capable of giving rise to neurons and glia of the central nervous system (CNS). [1] [2] [3] [4] These cells are present in the developing and adult CNS, and can be isolated and expanded in vitro using mitogenic factors, such as epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). 5 However, growth factors are not ideal candidates as drugs of support in protocols of cell replacement therapy because of their limited central bioavailability. Little is known on how G-proteincoupled receptors affect the physiology of NPCs, although these receptors are targeted by a large number of drugs. Here, we focus on metabotropic glutamate (mGlu) receptors, which are implicated in the regulation of developmental plasticity. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] mGlu receptors form a family of eight subtypes, of which mGlu1 and mGlu5 are coupled to polyphosphoinositide (PI) hydrolysis, whereas all other subtypes are negatively coupled to adenylyl cyclase in heterologous expression systems. 17, 18 Although mGlu receptors regulate synaptic transmission, some of the subtypes (particularly, the mGlu5 receptor) are expressed at developmental stages that precede synaptic formation and are also found in nonneuronal tissues. [19] [20] [21] A specific role for mGlu5 receptors in developmental plasticity is suggested by numerous observations. For example, endogenous activation of mGlu5 receptors in immature cortical neurons generates calcium oscillations, 12 and homozygous null mutations of either mGlu5 receptors or phospholipase C-b1 disrupt the cytoarchitectural differentiation of 'barrels' in the mouse somatosensory cortex. 13 Endogenous activation of mGlu5 receptors is also required for the maturation and survival of cultured cerebellar granule cells. 16, 22 Whether mGlu5 receptors or other mGlu receptor subtypes are involved in the regulation of NPCs in the CNS is unknown. We now report that two mGlu receptor subtypes, that is mGlu3 and mGlu5, are expressed by NPCs, and that endogenous activation of mGlu5 receptors in particular controls the proliferation and/or survival of NPCs both in vitro and in vivo.
(clone J1) (Tuj1)) markers ( Figure 1) . None of the nestin þ cells was positive for TuJ1 and less than 0.5% of cells coexpressed GFAP. When plated in the absence of mitogens, NPCs differentiated into astrocytes, neurons or oligodendrocytes as assessed by immunostaining for GFAP, Tuj1 and galactocerebroside (GalC), respectively (Figure 1b, c, d) . NPC cultures at 4-6 passages grown under proliferating conditions expressed mGlu3, mGlu4, mGlu5 and mGlu7 receptor mRNA, whereas only mGlu3 and mGlu5 receptor mRNA was detected at later passages (Figure 2a) . Expression of mGlu3 and mGlu5 receptor proteins is shown in Figure 2b . The density of both receptors was greater in cultures at 410 passages. For this reason, we have performed most of the experiments in cultures at 12-14 passages. In these cultures, activation of mGlu5 receptors with the selective agonist quisqualate (applied in combination with the AMPA receptor antagonist 1,2,3,4-tetrahydro6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX) stimulated PI hydrolysis (Figure 2c) , that is the classical transduction pathway associated with mGlu5 receptors.
Stimulation by quisqualate was abolished by the mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) (Figure 2c ). MPEP is a selective noncompetitive antagonist of mGlu5 receptors and therefore, by definition, can block mGlu5 receptors independently of the concentrations of ambient glutamate. 23 In addition, MPEP inhibits the constitutive activity of mGlu5 receptors (i.e. receptor activity in the absence of any ligand), behaving as an inverse agonist. 24 Addition of quisqualate þ NBQX also activated the mitogenactivated protein kinase (MAPK) pathway (Figure 2e ). The action of quisqualate was mimicked by the selective mGlu1/5 receptor agonist 3,5-dihydroxyphenylglycine (DHPG, 100 mM), which, however, was less efficacious in stimulating PI hydrolysis and the MAPK pathway (not shown). We could not detect any stimulation of the phosphatidylinositol-3-kinase (PI-3-K) pathway by either quisqualate or DHPG because the background levels of phosphorylated Akt were too high even after 4 h of withdrawal from EGF and bFGF (not shown). mGlu3 receptors expressed by cultured NPCs were also functional, as shown by the ability of the and by a reduction in cyclin D, cyclin A2 and cyclin B1 mRNA levels ( Figure 3b ). This effect was associated with an increase in the spontaneous death of cultured NPCs, as shown by a greater percentage of cells harboring hypoploid DNA (Figure 4a ) and by increases in LDH release ( Figure 4b ) and caspase-3 activity (Figure 4c ), suggesting that a percentage of NPCs died by apoptosis followed by secondary necrosis. The combined effects of mGlu receptor antagonists on cell proliferation and survival were confirmed by the microscopic analysis of neurosphere diameters, which progressively increased with time in culture. During the 4 days of treatment, we measured the neurosphere diameters every day in comparable fields for each dish. Treatment of NPCs with MPEP or LY341495 reduced the percentage of neurospheres with large diameters since the first day of exposure. Cultures treated with MPEP or high concentrations of LY341495 (which inhibit mGlu3, mGlu5 and other mGlu receptor subtypes) showed a multimodal distribution of neurosphere diameters ( Figure 5 ). Cell proliferation was also assessed using a quantitative proliferation assay that is based on the conversion of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) into formazan (see Materials and Methods). Using this assay, we have extended the study to NPC cultures at four passages and to cultures obtained from mGlu5 receptor knockout mice.
The two antagonists that we have tested (i.e. MPEP and LY341495 at low and high concentrations) reduced cell proliferation rate in cultures at four and 12 passages from wild-type mice (results of cultures at four passages are shown in Figure 6 ). LY341495 was more effective at 3 mM (when it loses its selectivity for mGlu2/3 receptors) than at 100 nM, suggesting that blockade of both mGlu2/3 and mGlu5 receptors contributes to reduce cell proliferation. NPC cultures from mGlu5 knockout mice (tested only at four passages) showed a lower proliferation as compared to cultures from wild-type mice ( Figure 6 ). Cultures from knockout mice were not responsive to the antiproliferative action of MPEP, whereas they were still responsive to LY341495, but without difference between low and high concentrations of the drug ( Figure 6 ). We also examined whether pharmacological agonists of mGlu3 or mGlu5 receptors could affect cell proliferation and survival despite the presence of the endogenous agonist (i.e. glutamate) in the medium. Cultures treated with quisqualate þ NBQX for 3 days had a greater percentage of cycling cells (Figure 3a) , showed a dramatic rise in the transcripts of most of the cyclins involved in the regulation of cell cycle (particularly cyclin A2, B1, D1 and D2) (Figure 3b ) and showed an increased percentage of neurospheres with large diameters ( Figure 5 ). Pharmacological activation of mGlu5 receptors had no discernible effect on the spontaneous death of NPCs in culture (see Figure 4a and b). DHPG (100 mM) mimicked the action of quisqualate þ NBQX (not shown). Treatment with the potent mGlu2/3 receptor agonist LY379268 (100 nM) produced no discernible changes in the distribution of cell cycle phases (Figure 3a ) in spite of a small rise in cyclin A2 and cyclin B1 mRNA levels (Figure 3b) . A 3-day treatment of cultures with LY379268 increased the percentage of neurospheres with large diameters similarly to that observed with quisqualate þ NBQX ( Figure 5 ). LY379268 had no apparent effects on NPC survival in culture (Figure 4a ). mGlu5 receptor blockade reduces the number of progenitor cells in zones of active neurogenesis of the adult mouse forebrain
To examine whether mGlu receptors could also control the proliferation rate of NPCs in their native environment, we treated adult mice with bromodeoxyuridine (BrdU) (50 mg/kg, i.p., injected 2 times/day for 4 days) and counted the number of proliferating cells in two zones of active neurogenesis: the dentate gyrus (DG) of the hippocampus and the subventricular zone (SVZ). The following groups of mice were examined: wild-type mice; mGlu5 knockout mice; wild-type mice implanted subcutaneously with an osmotic minipump containing saline; and mice implanted with minipumps releasing for 7 days MPEP, LY379268, LY341495 or LY379268 þ LY341495 (all at 1 mg/kg/day). All these drugs are centrally bioavailable. We could not inject quisqualate or DHPG intracerebroventricularly because both drugs are known to induce motor seizures. BrdU þ cells were counted in comparable microscopic sections by an observer who was unaware of the treatments. Interestingly, all mGlu5À/À mice showed a much smaller ventricular cavity (compare 
receptors is required for an optimal proliferation and survival of stem/progenitor cells in the adult forebrain. Infusion with LY341495 reduced the number of BrdU þ cells in the DG and to a lesser extent also in the SVZ. However, this action was unaffected by coinfusion with the mGlu2/3 receptor agonist LY379268. When infused alone, LY379268 had no effect on the number of proliferating cells in the SVZ but, unexpectedly, it lowered cell number in the DG, thus mimicking the action of the antagonist LY341495 (Figure 7d and h) .
Discussion
NPCs offer the promise of novel repair strategy in the injured CNS. Their unique characteristics are object of intense investigation aimed at identifying the mechanisms that allow their positive enrichment both in vitro and in vivo. We have examined whether these mechanisms involve mGlu receptors because (i) the native environment of NPCs is rich in extracellular glutamate and (ii) mGlu receptors are widely implicated in the regulation of developmental plasticity (see Introduction). We have found that NPCs in culture express mGlu5 receptors coupled to their canonical transduction pathways, that is, the stimulation of PI hydrolysis and MAP kinase activation. 18, [26] [27] [28] [29] The use of MPEP and mGlu5 knockout mice showed that endogenous activation of mGlu5 receptors supports the proliferation and survival of NPCs in cultures, as well as in zones of active neurogenesis of the adult brain. This is a relevant finding because it discloses a novel aspect in the biology of NPCs. Interestingly, mGlu5 is the only mGlu receptor subtype detectable in large amounts in the embryonic life, and is expressed by endogenous NPCs in the developing and adult brain. 30 The lower number of proliferating cells found in the DG and SVZ of mGlu5 knockout mice in spite of a normal brain morphology suggests that compensatory mechanisms might have occurred in these animals. However, it is noteworthy that mGlu5 knockout mice show behavioral abnormalities that may be consistent with a reduced proliferation of endogenous NPCs, including deficits in sensory-motor gating 31 and spatial learning. 32 Addition of mGlu5 receptor agonists to cultured NPCs supported cell proliferation in spite of the high concentrations of extracellular glutamate, indicating that the receptor was not Figure 5 Pharmacological modulation of mGlu3 and mGlu5 receptors affects the diameter of neurospheres in cultured NPCs grown under proliferating conditions. The distribution of neurospheres by their diameter is shown after 1-3 days of exposure to MPEP, LY341495, quisqualate þ NBQX or LY379268. Each drug was applied daily starting from the time of plating. Each value represents the mean of three determinations. S.D. was always less than 10% of the mean value. *Po0.05 (two-way ANOVA þ Bonferroni's t-test) versus the respective controls. Note that antagonists (MPEP, LY341495) decreased the diameters of neurospheres, whereas an opposite effect was induced by agonists (quisqualate þ NBQX or LY379268). NBQX alone did not affect the diameter of neurospheres (not shown) Figure 6 Cell proliferation in cultured NPCs prepared from wild-type or mGlu5 receptor knockout mice. Cell proliferation was assessed by the MTS assay after 4 days of treatment with the indicated drugs. Values are expressed as optical density (OD)/plate and represent the means þ S.E.M. of four determinations. Po0.05 (one-way ANOVA þ Dunnett's t-test) versus (*) the respective control groups; (#) the 'wild-type groups treated with MPEP or with 100 nM LY341495; and (y) the corresponding values of wild-type cultures mGlu receptors and neural progenitor cells V Di Giorgi-Gerevini et al endogenously saturated. The large induction of all cyclins observed in response to a 3-day treatment with quisqualate was unexpected because cells had not been arrested and were exposed to mitogens (EGF and bFGF) since the time of plating. One possible explanation is that activation of mGlu5 receptors synchronizes groups of NPCs to proliferate. This process may involve the release of calcium from intracellular stores and the generation of intercellular calcium waves, as shown in cultured astrocytes challenged with glutamate. [33] [34] [35] This 'synchronizing' activity of mGlu5 receptors might contribute to explain the heterogenous response of NPC cultures to MPEP or high concentrations of LY341495, as revealed by a distribution pattern of neurosphere diameters with multiple peaks (see Figure 5) . Activation of mGlu5 receptors could also support NPC proliferation by stimulating the MAPK pathway, similarly to that observed for muscarinic 36, 37 or opioid 38 receptor activation. We conclude that mGlu5 receptors act as physiological regulators of NPC proliferation, and that mGlu5 receptor agonists may facilitate the expansion of NPCs in culture. The use of these drugs in vivo is limited by their toxicity and their poor brain penetration. The use of positive allosteric modulators of mGlu5 receptors may help to overcome these limitations. 39 The role of mGlu3 receptors in the regulation of NPC proliferation and survival is less clear. In culture, selective blockade of these receptors with nanomolar concentrations of LY341495 25 reduced NPC proliferation and survival. These concentrations were also effective in cultures from mGlu5 knockout mice, suggesting that endogenous activation of mGlu3 receptors supports NPC proliferation independently of the presence of mGlu5 receptors. Treatment with LY379268, a potent mGlu2/3 receptor agonist, 25 induced small changes in the expression of cyclin mRNA, and increased the percentage of neurospheres with large diameters. Results obtained in mice treated with mGlu2/3 receptor ligands are difficult to explain. A 7-day treatment with LY341495 reduced the number of proliferating NPCs in the SVZ and DG, but its action was not affected by the combined administration of LY379268. Whether this lack of competition is due to a different central bioavailability of the two drugs (due to a different brain penetration or peripheral metabolism) is unknown at present. Studies with multiple doses of LY379268 are needed to clarify this issue. LY379268 injected alone affected NPC number in the DG but not in the SVZ, which may simply reflect the different nature of dividing cells present in these two regions. 40 Unexpectedly, treatment with LY379268 reduced the number of NPCs in the DG. This paradoxical effect might be related to the known ability of mGlu2/3 receptor agonists to reduce glutamate release in the DG, 41 thus limiting the endogenous activation of mGlu receptors expressed by NPCs. On the other hand, we cannot exclude that, in in vivo studies, LY341495 might have recruited receptor subtypes other than mGlu2 or mGlu3, including the mGlu5 receptor itself. The use of mGlu3 knockout mice may help solve this caveat.
In conclusion, our results indicate that at least mGlu5 receptors are critically involved in the regulation of NPC proliferation and survival. A reduced proliferation of NPCs may limit the endogenous repair mechanisms when mGlu5 receptor antagonists are used as neuroprotective agents in neurodegenerative disorders. 42, 43 Materials and Methods 
Cultures of NPCs
NPCs were isolated from the forebrain of C57 black wild-type mice or from mGlu5 receptor knockout mice (purchased from Jackson Laboratories, Bar Harbor, ME, USA) 43 at embryonic day 20 (E20). Briefly, the brain tissue was collected in HBSS, mechanically dissociated to a single cell suspension and then resuspended in serum-free medium in the presence of 20 and 10 ng/ml of human recombinant EGF and bFGF, respectively. The cell suspension was plated at 500 cells/cm 2 in untreated 25 cm 2 tissue culture flasks (Nunc, USA) and made to grow as neurospheres. The proliferating medium is a DMEM-F12 optimized for neural progenitor cell growth (Euroclone, Irvine, Scotland) containing 0.6% glucose, 9.6 g/ml putrescine, 6.3 ng/ml progesterone, 5.2 ng/ml sodium selenite, 0.025 mg/ml insulin and 0.1 mg/ml transferrin (sodium salt, grade II, Sigma). After 1 week, primary cultures were collected, mechanically dissociated and replated under the same conditions, in order to eliminate short-term dividing precursors. After dissociation, plated cells proliferate and give rise to secondary neurospheres. The cells were passaged every 5 days in the serum-free medium. The cells obtained as described above were immunopositive for nestin when grown as neurospheres, with less than 3% of cells expressing GFAP or Tuj1. Moreover, when grown in 5% of serum and after removal of mitogens, they were able, after 1 week, to differentiate into neurons (5%, as assessed by immunostaining for Tuj1), astrocytes (80-90%, as assessed by GFAP immunostaining) and oligodendrocytes (3-4%, as assessed by GalC immunoreactivity).
At the time of the experiment (passages 4 or 12-14), cells were plated in suspension in serum-free medium onto 35 mm Nunc Petri dishes at the initial density of 0.5 Â 10 6 cells/dish, and cultured for 4 days for the assessment of proliferation or survival. Drugs were applied daily for 3 days since the time of plating. Each treatment was run in triplicate. Images of cell cultures at different days of treatment were collected by a digital camera and the diameter of neurospheres was measured for each experimental condition.
Immunocytochemistry
In order to perform the staining in undifferentiated NPCs, the cells were plated on round coverslips and then centrifuged to make the spheres adherent. To stain the differentiated NPCs, the cells were plated in coated round coverslips, and differentiated with serum-containing medium for 10 days. Cultured NPCs (differentiated and undifferentiated) were fixed with 4% paraphormaldehyde for 15 min. Following incubation with 4% of normal goat serum in TBS for 1 h, the primary antibodies (Tuj1, Covance; GFAP, Sigma; GalC, Boehringer-Mannheim) were applied alone or in combination with the anti-nestin antibody (Chemicon) at 41C overnight. Cells were then washed three times and FITC-or TRITC-conjugated secondary antibodies (anti-mouse for Tuj1, GFAP and GalC; anti-rabbit for nestin) were applied for 1 h at room temperature in order to visualize the labelled sites. Fluorescence was detected by a Zeiss laser scanner microscope (LSM510, Oberkochen, Germany).
RT-PCR analysis
RT-PCR analysis of mGlu receptors was performed as described previously. 44 The following primers were used for each metabotropic glutamate receptor subtype indicated below: mGlu1: forward GCTGTA CCTACTATGCCTTC, reverse AGACCATGACACAGACTTGC; mGlu2: forward CTACAGTGATGTCTCCATCC, reverse AAAGCCTCAATGCCT GTCTC; mGlu3: forward CAAGTGACTACAGAGTGCAG, reverse CTGTC ACCAATGCTCAGCCTC; mGlu4: forward CCAACGAGGATGACATCA GG, reverse CACAGGTCACGGTGCATGG; mGlu5: forward GTCCTTCT GTTGATCCTGTC, reverse ATGCAGCATGGCCTCCACTC; mGlu6: forward GCCAGTCAGATGATTCCACC, reverse GCCTGGTACCTGGAA GATGTC; mGlu7: forward CCAGATGTGGCAGTGTGTTC, reverse CGA GTCTTGATGGCATACAC; mGlu8: forward ATCACCTTCAGCCTCATC TC, reverse TGTGACCACAGCCTTGAAGC.
For b-actin amplification, we used the primers described by Roelen et al., 45 which span an intron and yield products of different sizes depending on whether cDNA or genomic DNA is used as a template (400 and 600 bp, respectively).
Western blot analysis
Western blot analysis of mGlu receptor proteins was carried out as described previously 44 using polyclonal antibodies against mGlu1a, mGlu4, mGlu5, mGlu6, mGlu7, mGlu8 (Upstate Technology) and mGlu2/3 (Chemicon International, Temecula, CA, USA) receptors. 3 H]inositol phosphates accumulating during the reaction was measured as described previously. 6 
Measurement of PI hydrolysis

Measurement of intracellular cyclic AMP levels
Cells were incubated in Krebs-Henseleit buffer containing 0.5 mM isobutylmethylxanthine (IBMX) for 15 min at 371C under constant oxygenation. After addition of forskolin and/or mGlu receptor ligands, the incubation was continued for a further 20 min. The reaction was terminated by addition of an equal volume of ice-cold 0.8 N HClO 4 . Samples were sonicated and centrifuged at low speed. The supernatants were added to K 2 CO 3 and used for the assessment of cAMP by RIA (Amersham).
Cell cycle analysis
FACS analysis of cell cycle and DNA ploidy was carried out using a Coulter Elite flow cytometer after staining with propidium iodide (50 mg/ml) and treatment for 1 h with RNAse (100 mg/ml), as described previously. 46 The transcripts of all cyclins involved in the regulation of the cell cycle were measured by RNAse protection assay (RPA) (BD Riboquantt Multi-Probe Rnase Protection Assay System, mCYC-1).
Assessment of cell proliferation
Cell proliferation was evaluated by using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) according to the mGlu receptors and neural progenitor cells V Di Giorgi-Gerevini et al manufacturer's protocol. The assay is based on reduction of MTS to a colored formazan product, which is measured spectrophotometrically. Cells were plated in 96-well plates in triplicate and were treated with mGlu receptor ligands each day for 3 days. At the end of the treatment, cells were incubated at 371C in a 5% CO 2 incubator. Metabolically active cells were detected by adding 2 ml of MTS to each well. After 2 h of incubation, the plates were red on a Multilabel Counter (Victor2; PerkinElmer).
Assessment of cell death
Cell death was assessed by measuring: (i) the percentage of cells bearing hypoploid DNA (see the Cell cycle analysis section; (ii) LDH release using a commercial kit (Roche Diagnostics Sp A, Milan, Italy); and (iii) caspase-3 activity using the Apo-ONE Homogenous caspase 3-7 assay kit (Promega, Madison, WI, USA). Caspase mRNA levels were measured by RNAse Protection Assay (BD Riboquantt Multi-Probe Rnase Protection Assay System, mAPO-1).
In vivo experiments
Male C57/6N black mice (Charles River, Calco, Italy) were treated for 7 days with saline, MPEP, LY379268, LY341495 or LY341495 þ LY379268 by means of subcutaneously implanted osmotic minipumps (Alzet) containing 100 ml of a 200 mM solution of each drug. Minipumps release 500 nl/h corresponding to a cumulative dose of 1 mg/kg/day of the drugs. All mice were treated with BrdU (50 mg/kg, i.p., injected two times daily for 4 days) since the beginning of the drug treatment. Experiments were also carried out in mGlu5 receptor knockout mice and their controls. C57 black mice heterozygous for mGlu5 receptor gene deletion, obtained from The Jackson Laboratories (Bar Harbor, ME, USA), were bred to homozygosity. Homozygous females and males were fertile, but poor breeders. Thus, all mice were generated by heterozygous breeding. Mice were kept under environmentally controlled conditions (221C with 40% humidity) on a 12-h light/dark cycle with food and water ad libitum. Mice were identified by PCR analysis on tail samples after birth. The absence of mGlu5 receptors was then confirmed by Western blot analysis carried out in the olfactory bulbs when the brain was removed for the detection of BrdU þ cells (7 days after the first injection of BrdU). Experiments were performed following the Guidelines for Animal Care and Use of the National Institutes of Health.
BrdU immunohistochemistry
Mice brains were removed and fixed in 4% paraformaldehyde/PBS for 2 days at 41C and then cryoprotected in 30% sucrose for 3-7 days. Sagittal and coronal sections (10 mm thick) were cut at the cryostat and serially attached to gelatin-coated slices. Sections obtained as described above were permeabilized with 1 N HCl solution and then incubated with Na 2 B 2 O 4 (100 mM). Slides were permeabilized for 30 min in TBS containing 0.2% Triton X-100. This was followed by preincubation in TBS containing 4% NGS for 30 min. Sections were incubated overnight at 41C in primary monoclonal antibody against BrdU (Becton Dickinson). After PBS rinsing, the slices were incubated with the secondary antimouse biotinylated antibody (Vector Labs) and subsequently with ABC solution (Vector Labs). Staining was developed using the DAB substrate kit for peroxidase (Vector Labs). Finally, sections were rinsed in TBS, dehydrated in increasing concentrations of ethanol, clarified and mounted on coverslips in a xylene-based mounting medium. Sections were viewed and photomicrographs were taken using an Olympus IX 50 microscope equipped with a Spot camera (Spot RT camera from Diagnostic Instruments Inc., Houston, TX).
